Background
Due to the shortage of professionals, the ever-increasing needs and demands for appointments, consultation of physicians is getting harder, and delays are getting longer. To limit this issue, several countries have experimented different models of independent prescribing through pharmacies.
Aim
This study aimed to analyze the contribution of independent prescribing by community pharmacists, in primary care, using the micro, meso, macro level framework.
Method
Three different databases were used: Medline, Scopus and Embase. The search was executed on March 23rd, 2022, for each of them. Some relevant articles were added manually to the search. To be selected for the review, articles needed to be published after 2000, written in English or French, focus on independent prescribing by community pharmacists, and concern a minor condition. Original research was accepted. Articles were imported into the Covidence systematic review software to perform the review.
Results
The search resulted in 1768 articles and 846 after removing duplicates. After title and abstract screening, 792 articles were qualified as irrelevant, and 54 full text studies were reviewed for eligibility. Finally, eight studies were included in the scoping review. The various studies included are recent (from 2013 to 2021) and mostly of Canadian origin (6/8). For five of them, a quantitative study design is observed. As an independent prescriber, the community pharmacist can improve patient access to primary care, reducing consultation delays for minor conditions. In addition, patient safety is maintained, and the patient’s quality of life is increased. The pharmacist independent prescriber model seems to be cost-effective for society.
Conclusion
This review highlights the potential value and relevance of the pharmacist independent prescriber. The benefits to society are felt at all levels: micro, meso, and macro. Effectiveness and efficacy seem established, but further studies are needed in other fields, as efficiency.